Overdose Symptoms of overdose strofantinom-T varied. Cardio-vascular system: arrhythmia, including bradycardia, AV-block, ventricular tachycardia or extrasystole, ventricular fibrillation. On the part of the digestive tract: anorexia, nausea, vomiting, diarrhea. On the part of the central nervous system and sensory organs: headache , fatigue. dizziness, rarely – staining the surrounding objects in green and yellow colors, a sense of flicker flies before his eyes, blurred vision, scotoma, macro- and micropsia: very rarely confusion, sinkoialnye state. With the development of glycoside intoxication drug buy testosterone propionate should be discontinued; assign the patient potassium supplements, parenteral administration unitiola, symptomatic therapy.
Testosterone enanthate ( USAN , BAN ) (brand names Delatestryl , Testostroval , Testro LA , Andro LA , Durathate , Everone , Testrin , Andropository ), or testosterone heptanoate , is an androgen and anabolic steroid and a testosterone ester .    Along with testosterone cypionate and testosterone propionate , it is one of the most widely used testosterone esters.  Testosterone enanthate was first introduced in 1952.  Administered via intramuscular injection , it is the most widely used form of testosterone in androgen replacement therapy . 
Testosterone, like many anabolic steroids, was classified as a controlled substance in 1991. Testosterone is administered parenterally in normal and delayed-release (depot) forms. In September 1995, the FDA approved testosterone transdermal patches (Androderm), and many transdermal forms and brands are now available including implants, gels, and topical solutions. A testosterone buccal system, Striant, was FDA-approved in July 2003; Striant is a mucoadhesive product that adheres to the buccal mucosa and provides a controlled and sustained release of testosterone. In May 2014, the FDA approved an intranasal gel formulation of testosterone (Natesto). A transdermal patch (Intrinsa) for hormone replacement in women is under investigation; the daily dosages used in women are much lower than for products used in males. The FDA refused approval for Intrinsa in 2004 stating that more data regarding safety, especially in relation to cardiovascular and breast health, were required.